Details for Patent: 11,878,022
✉ Email this page to a colleague
Which drugs does patent 11,878,022 protect, and when does it expire?
Patent 11,878,022 protects INZIRQO and is included in one NDA.
Summary for Patent: 11,878,022
| Title: | Hydrochlorothiazide compositions |
| Abstract: | Disclosed herein is a powder for oral suspension and a reconstituted product thereof comprising highly pure hydrochlorothiazide, which is useful for treating hypertension and edema. |
| Inventor(s): | Muthusamy Shanmugam, Subramaniam ARUNKUMAR |
| Assignee: | Novitium Pharma LLC |
| Application Number: | US18/053,197 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 11,878,022 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
Drugs Protected by US Patent 11,878,022
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novitium Pharma | INZIRQO | hydrochlorothiazide | FOR SUSPENSION;ORAL | 219141-001 | Jan 28, 2025 | RX | Yes | Yes | 11,878,022 | ⤷ Start Trial | Y | TREATMENT OF EDEMA IN PATIENTS WHO ARE IN NEED OF AN ORAL LIQUID SUSPENSION OF HYDROCHLOROTHIAZIDE | ⤷ Start Trial | |||
| Novitium Pharma | INZIRQO | hydrochlorothiazide | FOR SUSPENSION;ORAL | 219141-001 | Jan 28, 2025 | RX | Yes | Yes | 11,878,022 | ⤷ Start Trial | Y | TREATMENT OF HYPERTENSION IN PATIENTS WHO ARE IN NEED OF AN ORAL LIQUID SUSPENSION OF HYDROCHLOROTHIAZIDE | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
